HC Wainwright & Co. Maintains Buy on Coherus BioSciences, Lowers Price Target to $11
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Douglas Tsao maintains a Buy rating on Coherus BioSciences (CHRS) but lowers the price target from $13 to $11.

March 20, 2024 | 11:19 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Coherus BioSciences' price target was lowered from $13 to $11 by HC Wainwright & Co., though the Buy rating was maintained.
The reduction in price target could have a mixed impact on CHRS's stock price in the short term. While the lowered target might initially concern investors, the maintenance of a Buy rating by a reputable analyst could offset negative sentiment, suggesting a belief in the company's underlying value and potential for growth.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 90